Login to Your Account


Expanded Astellas deal to advance Cytokinetics muscle biology in ALS

By Jennifer Boggs
Managing Editor

Thursday, July 28, 2016

As the amyotrophic lateral sclerosis (ALS) community hailed work published this week identifying a new gene linked to the disease, Cytokinetics Inc. and Astellas Pharma Inc. strengthened their existing skeletal muscle activator deal with a focus on ALS, including an option to Astellas for rights to tirasemtiv, currently being tested in the phase III VITALITY-ALS study that could lead to approval applications in the U.S. and Europe.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription